Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jul 24, 2024

Luke Piggott, principal scientist at Debiopharm, has a unique business model in the drug discovery and development to commercialization landscape. Focusing on rare cancers, they license drugs from smaller biotechs and conduct clinical trials before out-licensing them to larger pharmaceutical companies with marketing capabilities. The use of AI is expanding biomarker discovery and the identification of potential novel mechanisms for targeted therapies.  Novel-novel combinations are being explored to provide therapies with more selective profiles with fewer side effects.

Luke explains, "Rare cancers is an interesting area. I mean, it’s never an easy one to be developing in the space of rare cancers. With a business model like ours, we have the opportunity to take some of these assets that perhaps are not as, shall we say, financially attractive to investors because of the smaller market opportunity. As a privately owned company, we have the ability to develop these kinds of drugs and move them ahead with solid financial backing. And so I think that’s one of the areas that we have the opportunity where some other companies would not."

"We do see overlap there with other diseases, although they may be morphologically different than the current specific sites that are more rare than other diseases. These underlying mechanisms are consistent across the different types of cancers. Now that we’re in the era of precision medicine and going after specific key oncogenic drivers of these tumors, it does allow potential opportunities to treat them in a more similar fashion, shall we say, to the larger populations or at least re-purpose some of those drugs and try them out on these rarer diseases."

#Debiopharm #RareDiseases #RareCancers #DrugDevelopment #PrecisionMedicine #BiotechInvestment

Debiopharm.com

Download the transcript here

Debiopharm